Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company